Marques da Silva, PAguiar, CMorais, JDISGEN-LIPID study Investigators2021-09-282021-09-282019Rev Port Cardiol (Engl Ed). 2019 Aug;38(8):559-569.http://hdl.handle.net/10400.17/3857Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in Portugal. Hypercholesterolemia has a causal role in atherosclerotic CVD. Guidelines recommend that cardiovascular (CV) risk reduction should be individualized and treatment goals identified. Low-density lipoprotein cholesterol (LDL-C) is the primary treatment target. Methods: DISGEN-LIPID was a cross-sectional observational study conducted in 24 centers in Portugal in dyslipidemic patients aged ≥40 years, on lipid-lowering therapy (LLT) for at least three months and with an available lipid profile in the previous six months. Results: A total of 368 patients were analyzed: 48.9% men and 51.1% women (93.9% postmenopausal), of whom 73% had a SCORE of high or very high CV risk. One quarter had a family history of premature CVD; 31% had diabetes; 26% coronary heart disease; 9.5% cerebrovascular disease; and 4.1% peripheral arterial disease. Mean baseline lipid values were total cholesterol (TC) 189 mg/dl, LDL-C 116 mg/dl, high-density lipoprotein cholesterol (HDL-C) 53.5 mg/dl, and triglycerides (TG) 135 mg/dl. Women had higher TC (p<0.001), LDL-C (non-significant) and HDL-C (p<0.001), and lower TG (p=0.002); 57% of men and 63% of women had LDL-C>100 mg/dl (p=0.28), and 58% of men and 47% of women had LDL-C>70 mg/dl (p=0.933). Conclusion: These observational data show that, despite their high-risk profile, more than half of patients under LLT, both men and women, did not achieve the recommended target levels for LDL-C, and a large proportion also had abnormal HDL-C and/or TG. This is a renewed opportunity to improve clinical practice in CV prevention.engHSM MEDAdultAgedFemaleMaleBiomarkers / bloodCardiovascular Diseases / epidemiologyCardiovascular Diseases / etiologyCardiovascular Diseases / prevention & controlCross-Sectional StudiesDyslipidemias / bloodDyslipidemias / complicationsDyslipidemias / drug therapyHumansHypolipidemic Agents / therapeutic useLipids / bloodMiddle AgedMorbidity / trendsPortugal / epidemiologyRegistriesRetrospective StudiesSurvival Rate / trendsjournal article10.1016/j.repc.2019.02.009. E